Graves' Orbitopathy. Группа авторов

ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 2002;240:515–520.

14 Campi I, Vannucchi G, Salvi M: Therapy of endocrine disease. Endocrine dilemma: management of Graves’ orbitopathy. Eur J Endocrinol 2016;175: R117–R133.

15 Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A: Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992;326:1733–1738.

16 Vannucchi G, Campi I, Covelli D, Dazzi D, Currò N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M: Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 2009;94:3381–3386.

17 Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O: TSH-receptor autoimmunity in Graves’ disease after therapy with antithyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study Eur J Endocrinol 2008;158:69–75.

18 Tallstedt L, Lundell G, Blomgren H, Bring J: Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130:494–497.

19 Chan W, Wong GW, Fan DS, Cheng AC, Lam DS, Ng JS: Ophthalmopathy in childhood Graves’ disease. Br J Ophthalmol 2002;86:740–742.

20 Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, Brook MG, Churchill D, de Ruiter A, Robinson S, Lacey CJ, Weetman AP: Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005;84:98–106.

21 Baker G, Mazziotti G, von Ruhland C, Ludgate M: Reevaluating thyrotropin receptor-induced mouse models of Graves’ disease and ophthalmopathy. Endocrinology 2005;146:835–844.

22 Moshkelgosha S, So P-W, Deasy N, Diaz-Cano S, Banga JP: Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves’ orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology 2013;154:3008–3015.

23 Berchner-Pfannschmidt U, Moshkelgosha S, Diaz-Cano S, Edelmann B, Görtz G-E, Horstmann M, Noble A, Hansen W, Eckstein A, Banja JP: Comparative assessment of female mouse model of Graves’ orbitopathy under different environments, accompanied by pro-inflammatory cytokine T cell responses to thyrotropin hormone receptor antigen. Endocrinology 2015;157:1673–1682.

24 Görtz G-E, Moshkelgosha S, Jesenek C, Horstmann M, Edelmann B, Banga JP, Eckstein A, Berchner-Pfannschmidt U: Pathogenic phenotype of adipogenesis and hyaluronan in orbital fibroblasts from female Graves’ orbitopathy mouse model. Endocrinology 2016;157:3771–3778.

25 Bell A, Gagnon A, Dods P, Papineau D, Tiberi M, Sorisky A: TSH signalling and cell survival in 3T3L1 preadipocytes. Am J Physiol Cell Physiol 2002;283:C1056–C1064.

26 Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS: Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma),and thyrotropin receptor by PPARgamma agonist inhuman orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 2002;87:2352–2358.

27 Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF: TSH-R expression and cytokine profile in orbital tissue of active vs inactive Graves’ ophthalmopathy patients. Clin Endocrinol (Oxf ) 2003;58:280–287.

28 Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M: Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci 2006;47:5197–5203.

29 Kohn LD, Alvarez F, Marcocci C, Kohn AD, Corda D, Hoffman WE, Tombaccini D, Valente WA, de Luca M, Santisteban P: Monoclonal antibody studies defining the origin and properties of autoantibodies. Ann NY Acad Sci 1986;475:157–173.

30 Weightman DR, Perros P, Sherif IH, Kendall-Taylor P: Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 1993;16:251–257.

31 Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ: Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003;170:6348–6354.

32 Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG: Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 2008;18:983–988.

33 Smith TJ, Hoa N: Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004;89:5076–5080.

34 Tsui S, Naik V, Hoa N, Hwang CJ, Afifryan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ: Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol 2008;181:4397–4405.

35 Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC: TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab 2016;101:2340–2347.

36 Prabhakar BS, Bahn RS, Smith TJ: Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003;24:802–835.

37 Fruhbeck G, Becceril S, Sainz N Garrastuchu P, Garcia-Vellosa MJ: BAT: a new target for human obesity? Trends Pharmacol Sci 2009;30:387.

38 Drexhage HA: Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves’ disease? Endocrinology 2006;147:9–12.

39 El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L: The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur